166 related articles for article (PubMed ID: 37120335)
1. Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu's Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011.
Cavillon A; Porcher R; Filleron T
Eur Urol; 2023 Jul; 84(1):e22-e23. PubMed ID: 37120335
[No Abstract] [Full Text] [Related]
2. Re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011.
Zhao B; Zhang R; Wu J
Eur Urol; 2023 Jul; 84(1):e20-e21. PubMed ID: 37121849
[No Abstract] [Full Text] [Related]
3. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
[No Abstract] [Full Text] [Related]
4. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
[No Abstract] [Full Text] [Related]
5. Reply to Mengda Zhang and Long Wang's Letter to the Editor re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024.
Amparore D; Checcucci E; Fiori C; Porpiglia F
Eur Urol; 2020 Jun; 77(6):e163-e164. PubMed ID: 32279902
[No Abstract] [Full Text] [Related]
6. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
Noel J; Huillard O; Goldwasser F
Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
[No Abstract] [Full Text] [Related]
7. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
Singla N; Margulis V
Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
[No Abstract] [Full Text] [Related]
8. Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796380
[No Abstract] [Full Text] [Related]
9. Reply to Mattias Höglund's Letter to the Editor re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020.
Klümper N; Cox A; Eckstein M
Eur Urol; 2023 Aug; 84(2):e51-e52. PubMed ID: 37244816
[No Abstract] [Full Text] [Related]
10. Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
Eur Urol; 2024 Apr; 85(4):e122-e123. PubMed ID: 37775361
[No Abstract] [Full Text] [Related]
11. Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory.
Sathianathen NJ; Konety BR
Eur Urol; 2019 Jul; 76(1):e10-e11. PubMed ID: 30665809
[No Abstract] [Full Text] [Related]
12. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
Mehra N; Dolling D; de Bono J
Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
[No Abstract] [Full Text] [Related]
13. Reply to Behnam Shakiba's Letter to the Editor re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.020.
Seizilles de Mazancourt E; Kaulanjan K
Eur Urol; 2024 Feb; ():. PubMed ID: 38388257
[No Abstract] [Full Text] [Related]
14. Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman's Letter to the Editor Re: Nicolò Maria Buffi, Giovanni Lughezzani, Rodolfo Hurle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.022.
Buffi NM; Lughezzani G; Hurle R; Lazzeri M; Taverna G; Bozzini G; Bertolo R; Checcucci E; Porpiglia F; Fossati N; Gandaglia G; Larcher A; Suardi N; Montorsi F; Lista G; Guazzoni G; Mottrie A
Eur Urol; 2017 Mar; 71(3):e92-e93. PubMed ID: 27641789
[No Abstract] [Full Text] [Related]
15. Reply to Meny Lv, Xufei Luo, and Yaolong Chen's Letter to the Editor re: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, et al. European Association of Urology Guidelines on Male Urinary Incontinence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.012.
Gacci M; Sakalis VI; Karavitakis M; Gravas S
Eur Urol; 2022 Oct; 82(4):e119-e120. PubMed ID: 35945088
[No Abstract] [Full Text] [Related]
16. Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796382
[No Abstract] [Full Text] [Related]
17. Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012.
Kerkmeijer LGW; Pos FJ; van der Heide UA; Israël B; Draulans C; Haustermans K
Eur Urol; 2022 Jun; 81(6):e147-e148. PubMed ID: 35339319
[No Abstract] [Full Text] [Related]
18. Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
Valle LF; Kishan AU
Eur Urol; 2021 Jul; 80(1):e15-e16. PubMed ID: 33934928
[No Abstract] [Full Text] [Related]
19. Reply to Rui-Cheng Wu, Deng-Xiong Li, and De-Chao Feng's Letter to the Editor re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85:146-53.
Eppler M; Ganjavi C; Abreu A; Gill I; Cacciamani GE
Eur Urol; 2024 Mar; 85(3):e85-e86. PubMed ID: 38182492
[No Abstract] [Full Text] [Related]
20. Reply to Ping Zhong, Xin Liu, and Limin Liao's Letter to the Editor re: Michele Gnech, Lisette 't Hoen, Alexandra Zachou, et al. Update and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.005.
Gnech M; 't Hoen L; Burgu B; Radmayr C
Eur Urol; 2024 May; ():. PubMed ID: 38735821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
